All
Results: 5869-5880 of 76126

Beacon Therapeutics Announces Positive 12-Month Safety and Efficacy Update from Phase 2 DAWN Trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2026 Annual Meeting

Paratus Energy Services Ltd. - Issues notice to holders of Notes to redeem Senior Secured Notes due 2026 in full









